MedPacto granted a European patent for their diagnostic kit detecting cancer cells in the blood
Nov 16, 2022
Diagnosing cancer by measuring the expression level of BAG2 protein in the blood…
The clinical trial is expected after testing prototype this year
MedPacto (CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, announced that they have obtained the European patent for their diagnostic kit that can detect cancer cells in the blood on November 15th.
The patent is for the diagnostic kit detecting cancer cells by measuring the expression level of the BAG2 protein in the blood. MedPacto had previously obtained Japanese and Australian patents in July this year following their Korean patent in March last year.
The patent will provide MedPacto with the exclusive right to develop diagnostic kits targeting BAG2 in Europe as well as in Korea, Japan, and Australia.
MedPacto is currently developing an investigational cancer diagnostic kit to detect metastasis and recurrence by targeting BAG2 as a diagnostic biomarker. MedPacto is expected to complete the prototype production this year and planning to proceed with its clinical trial next year.
As the study on ‘MA-B2’, antibody treatment targeting BAG2, has shown promise, antibody treatment along with diagnosing recurrence is expected to be available.
Seong-jin KIM, CEO of MedPacto, identified the mechanism of action for the BAG 2 protein regarding recurrence and metastasis of triple-negative breast cancer for the first time in the medicine. Seong-jin KIM has confirmed that there is a correlation between BAG2 protein and tumorigenicity by confirming an overexpression of BAG2 secreted out of cells in the blood of breast cancer patients when compared to that of healthy people.
In a recent study, BAG2 has been measured in patients’ blood with other types of cancers as well as TNBC indicating the diagnostic kit’s expandability to other types of cancers once it is commercialized.
"By detecting cancer with the BAG2 expression secreted by cancer cells in the blood, the new kit could confirm cancer prognosis faster than conventional biopsy or medical imaging tests. We’re expecting that the Japanese, and European patent registration following the Korean patent will expedite our entry into the global market.” stated a MedPacto representative.